Printer Friendly

Dunsire Named President, Chief Executive Officer at XTuit Pharmaceuticals.

M2 PHARMA-March 9, 2017-Dunsire Named President, Chief Executive Officer at XTuit Pharmaceuticals


- US-based biopharmaceutical company XTuit Pharmaceuticals, Inc. has appointed Deborah Dunsire, M.D., as president and chief executive officer, the company said.

She also joins the company's board of directors.

Dunsire brings more than two decades of strategic, clinical, commercial and management experience in the biotech and pharmaceutical industry.

She formerly served for eight years as president and chief executive officer of Millennium Pharmaceuticals, Inc., which became Takeda Oncology, and prior to that led the Novartis North American Oncology Business for more than ten years.

The appointment of Dunsire as president and chief executive officer occurs at a time when XTuit's pipeline of microenvironment-targeted drug candidates is advancing toward clinical development, with the ability to act through pleiotropic mechanisms to address multiple pathways that cause the disease-promoting microenvironment.

Based on recent progress, the company's most advanced drug candidates are being developed to enter clinical study for treatment of fibrotic disease, supported by XTuit's novel quantitative, tissue-based biomarker platform for efficacy prediction.

XTuit's proprietary, microenvironment-targeted drugs have applications in two major therapeutic areas: in fibrotic inflammatory diseases to potentially have unique, single agent, disease-reversing activity; and in cancer to have combination activity with immuno-oncology drugs and other cancer therapies.

Prior to joining XTuit, Dr. Dunsire was chief executive officer of Forum Pharmaceuticals (previously EnVivo Pharmaceuticals), a biopharmaceutical company developing therapies for central nervous system diseases.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 9, 2017
Previous Article:GSK hires Omongiade Ehighebolo as communications & government affairs director in West and Central Africa.
Next Article:Community Health Systems Pricing USD 2.2bn Notes Offering.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters